Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALN-6457 in Symptomatic Prion Disease
NCT07832370Phase 2Not yet recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Oct 2026
- Primary completion
- Feb 2031
01
Overview
Phase 2, open-label trial of ALN-6457 in Prion Disease (PD), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Occurrence of Treatment Emergent Adverse Events at 156 weeks, Severity of Treatment Emergent Adverse Events at 156 weeks and 1 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
ALN-6457
03
Conditions
Prion Disease (PD)
Beyond the preview
Go deeper on NCT07832370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07832370.